Share This Page
Drug Price Trends for REXULTI
✉ Email this page to a colleague
Average Pharmacy Cost for REXULTI
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| REXULTI 0.25 MG TABLET | 59148-0035-13 | 48.44015 | EACH | 2025-01-01 |
| REXULTI 1 MG TABLET | 59148-0037-13 | 48.44794 | EACH | 2025-01-01 |
| REXULTI 0.5 MG TABLET | 59148-0036-13 | 48.41947 | EACH | 2025-01-01 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for REXULTI
Overview of REXULTI
REXULTI, also known as brexpiprazole, is an atypical antipsychotic drug used in the treatment of schizophrenia and major depressive disorder (MDD). It is marketed by Otsuka and Lundbeck Pharmaceuticals.
Mechanism of Action and Clinical Use
REXULTI works by modulating the activity of various neurotransmitters in the brain, including dopamine and serotonin. This mechanism helps in managing symptoms of schizophrenia and MDD. The drug is available in various dosages, ranging from 0.25 mg to 4 mg oral tablets, and is administered once daily[4].
Market Scenario
The market for REXULTI is complex and influenced by several factors, including regulatory milestones, competition from other therapies, and the impact of generic erosion.
Current Market Position
As of the latest reports, REXULTI is a significant player in the markets for schizophrenia and MDD. However, it faces intense competition from both branded and generic products. In the MDD market, for instance, REXULTI competes with other established drugs like Trintellix and emerging therapies such as Auvelity and aticaprant[2].
Regulatory Milestones and Development Activities
The regulatory landscape for REXULTI includes several key milestones. The drug has been approved as an adjunctive therapy for adults with MDD and schizophrenia. Detailed reports provide insights into its regulatory history, research and development activities, and future market assessments across major markets including the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan[1][4].
Market Forecast
The market forecast for REXULTI indicates a mixed outlook. On one hand, the drug is expected to benefit from extensive research and incremental healthcare spending, which could expand the market size. However, the entry of cheaper generics due to patent expiries is anticipated to erode sales significantly, especially in markets like Japan[1][2].
-
Forecasted Sales: The report provides detailed forecasted sales data for REXULTI from 2023 to 2032. This includes market size projections in the seven major markets, which will help clients in decision-making regarding their therapeutic portfolios[1][4].
-
Competition and Emerging Therapies: The launch of late-stage emerging therapies is expected to impact the market significantly. New pipeline products with novel mechanisms of action, such as aticaprant, are forecasted to drive combined sales and pose a challenge to REXULTI's market dominance[2].
Price Analysis
Current Pricing
REXULTI is currently available as a brand-name drug only, with no generic version available. The cost for a 30-tablet supply of REXULTI can range from approximately $1,559 to $1,559.03, depending on the dosage and pharmacy[5].
| Dosage | Quantity | Per Unit Price | Total Price |
|---|---|---|---|
| 0.25 mg | 30 | $51.97 | $1,559.03 |
| 0.5 mg | 30 | $51.97 | $1,559.03 |
| 1 mg | 30 | $51.97 | $1,559.03 |
| 2 mg | 30 | $51.97 | $1,559.03 |
| 3 mg | 30 | $51.97 | $1,559.03 |
| 4 mg | 30 | $51.97 | $1,559.03 |
Cost Comparison
In a pharmacoeconomic review, REXULTI was compared to other antipsychotic drugs. The annual cost of brexpiprazole was found to be higher than that of generic and some branded competitors but lower than others. For example, it was more expensive than olanzapine and risperidone but less expensive than aripiprazole and lurasidone[3].
Impact of Generic Erosion
The patent expiries of REXULTI and other similar drugs are expected to lead to significant generic erosion. This will result in cheaper generic alternatives entering the market, which could erode the sales of branded products like REXULTI. This effect is particularly anticipated to be pronounced in the Japanese market, where several key products are facing patent expiries early in the forecast period[2].
SWOT Analysis and Analyst Views
Strengths
- Approved Indications: REXULTI has been approved for use in both schizophrenia and MDD, providing a broad therapeutic scope.
- Research and Development: Ongoing research and development activities are expected to enhance its market position.
- Market Presence: It has a significant presence in major markets, including the US, EU4, the UK, and Japan.
Weaknesses
- High Cost: The drug is expensive, which can be a barrier to adoption, especially with the availability of cheaper generics.
- Patent Expiry: The impending patent expiries will lead to generic competition, eroding sales.
Opportunities
- Emerging Markets: There is potential for growth in emerging markets where access to antipsychotic medications is limited.
- Novel Approaches: Developing therapies with novel mechanisms of action can help REXULTI stay competitive.
Threats
- Generic Competition: The entry of generic versions will significantly impact sales.
- Competing Therapies: New pipeline products with novel mechanisms of action pose a threat to REXULTI's market share.
Key Takeaways
- REXULTI is a significant player in the schizophrenia and MDD markets but faces intense competition.
- The drug's market forecast is influenced by regulatory milestones, generic erosion, and the launch of emerging therapies.
- High costs and impending patent expiries are key challenges.
- Ongoing research and development activities are crucial for maintaining market presence.
FAQs
What is REXULTI used for?
REXULTI (brexpiprazole) is used in the treatment of schizophrenia and major depressive disorder (MDD).
How much does REXULTI cost?
The cost for a 30-tablet supply of REXULTI can range from approximately $1,559 to $1,559.03, depending on the dosage and pharmacy.
What are the potential threats to REXULTI's market share?
The main threats include generic competition due to patent expiries and the launch of new pipeline products with novel mechanisms of action.
Is REXULTI available as a generic?
No, REXULTI is currently available only as a brand-name drug, with no generic version available.
What is the forecasted market scenario for REXULTI?
The market scenario is expected to change due to extensive research, incremental healthcare spending, and the impact of generic erosion. The launch of late-stage emerging therapies will also significantly impact the market.
Sources
- ResearchAndMarkets.com: "REXULTI Drug Insight and Market Forecast - 2032"[1].
- ClinicalTrialsArena: "Major depressive disorder market to reach $9.6bn across 8MM by 2029"[2].
- CADTH COMMON DRUG REVIEW: "Pharmacoeconomic Review Report for Rexulti"[3].
- PR Newswire: "REXULTI (brexpiprazole): Approved as Adjunctive Therapy to Treat Adults with MDD and Schizophrenia"[4].
- Drugs.com: "Rexulti Prices, Coupons, Copay Cards & Patient Assistance"[5].
More… ↓
